|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
GI Dynamics Announces New Insights into EndoBarrier™ Therapy’s Influence on Key Hormones Affecting Satiety and Blood Sugar Control
10/22/2012 9:51:05 AM
AMSTERDAM & LEXINGTON, Mass.--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX: GID) today announced data, presented during the 20th United European Gastroenterology Week (UEGW), which adds to the growing body of clinical and preclinical evidence of the influence EndoBarrier® Therapy may have on key intestinal hormones that control appetite and glucose metabolism. GI Dynamics and several of its collaborators have now shown in animal models and clinical studies that much like gastric bypass surgery, EndoBarrier Therapy affects critical metabolic hormones, including the gut peptides glucagon-like peptide-1 (GLP-1), gastric inhibitory peptide (GIP) and peptide YY (PYY), as well as insulin, glucagon, ghrelin and leptin.
|
|
|
|
|
|
|
|
|
|
|